An open-label, two-period, single-sequence, crossover study to evaluate the absolute bioavailability (ABA) and mass balance (MB) of alectinib in healthy male subjects

Trial Profile

An open-label, two-period, single-sequence, crossover study to evaluate the absolute bioavailability (ABA) and mass balance (MB) of alectinib in healthy male subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Alectinib (Primary) ; Alectinib (Primary) ; Alectinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 20 Apr 2016 New trial record
    • 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top